Progyny presents menopause research and Barclays holds Progyny stock at USD 30.00

Published on 10/16/2026 at 00:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Progyny's study will be presented October 22, 2026 at 5:15 p.m. PT in San Diego at the meeting. Barclays holds Progyny stock at USD 30.00.

Latest company developments

On October 15, 2026, Progyny scheduled a research presentation for October 22, 2026.
The October 7, 2026 selling season update pointed to 1.2 million new covered lives.
Barclays maintained a Hold rating with a USD 30.00 target on October 15, 2026.

PGNY, US74340E1038, Illustration mit AI erstellt.

Progyny announced on October 15, 2026 that it will present new menopause research at the October 20 to 24 meeting in San Diego, while Barclays maintained a Hold rating and a USD 30.00 price target. Both developments were reported by GlobeNewswire and Markets Insider.

Menopause research broadens the offer

The study examines access, engagement, and symptom changes among women using Progyny's employer-sponsored Menopause and Midlife program. Gloria Richard-Davis of Morehouse School of Medicine is scheduled to present the research, giving the company a concrete healthcare application beyond fertility and family building.

Progyny said the presentation reflects an expansion across the reproductive health continuum, including preconception, fertility, pregnancy, postpartum, menopause, and midlife. As of October 15, 2026, the company had a market capitalization of USD 2.1 billion.

Three milestones carry the story

On August 6, 2026, Progyny reported second-quarter revenue of USD 350.51 million and diluted earnings per share of USD 0.55, compared with USD 0.19 a year earlier, according to MarketBeat. On October 7, 2026, the company said its selling season could add 1.2 million new covered lives through launches in the first half of 2027, as reported by GlobeNewswire. The October 15 research announcement is the latest of the three milestones.

What does the expansion add?

The 1.2 million covered-lives outlook gives the newer menopause offering a broader commercial setting, while the study supplies an outcomes-based narrative for employers. That combination matters because Progyny is presenting both expected reach and clinical evidence as it expands beyond its established fertility platform.

The next presentation dates

The Menopause Society annual meeting runs from October 20, 2026, through October 24, 2026. The research presentation is scheduled for October 22, 2026, from 5:15 p.m. to 5:30 p.m. PT, according to GlobeNewswire.

Market value sets a reference

Progyny's USD 2.1 billion market capitalization as of October 15, 2026 places the research expansion in the context of a listed healthcare company with an established earnings base. The next investor question is whether new programs can convert broader coverage into recurring operating growth.